As antibiotic resistance has become a pressing health concern, Dutch biotech company Micreos developed antibiotic alternatives based on a completely different, targeted approach, using endolysins. Micreos' products have helped hundreds of thousands of people and received millions of investment and is now expanding across North America. As the first to market this innovative technology, what hurdles did Micreos face on its way to success and how did they overcome these?
NL
DE
